File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/cncr.24636
- Scopus: eid_2-s2.0-72249100065
- PMID: 19701904
- WOS: WOS:000271918600020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization
Title | The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization |
---|---|
Authors | |
Keywords | Elderly Hepatitis Hepatocellular carcinoma Transarterial chemoembolization |
Issue Date | 2009 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741 |
Citation | Cancer, 2009, v. 115 n. 23, p. 5507-5515 How to Cite? |
Abstract | BACKGROUND: The authors evaluated and compared the treatment outcomes of transarterial chemoembolization (TACE) between young (≤70 years) and elderly (>70 years) patients at their institute over an 18-year period. METHODS: Advanced hepatocellular carcinoma (HCC) patients who received TACE at the authors' center were analyzed retrospectively. The demographic data, TACE-related morbidities, and survival outcome were compared between these 2 age groups. RESULTS: Between 1989 and 2006, 843 patients who were ≤70 years old and 197 patients who were >70 years old received TACE treatment for advanced HCC. There were significantly more comorbid illnesses associated with the elderly patients than the young patients (64 % vs 33%, P < .01). Moreover, elderly patients who received TACE treatment for HCC were at earlier stages of disease (P < .01). Both the overall median survival (14.0 months vs 8.1 months, P < .003) and disease-specific survival (15.2 months vs 8.7 months, P < .001) were significantly higher in elderly than young patients. The most commonly encountered TACE-related morbidity in both age groups was liver function derangement. Young patients had a significantly higher rate of developing liver derangement after TACE than elderly patients (21% vs 11%, P < .01). Conversely, the elderly patients had a significantly higher rate of developing peptic ulcer disease with TACE treatment than young patients (2.5% vs 0.5%, P=.01). Overall, there was no significant difference in TACE-related mortality between the young and elderly patients (3% vs 4%, P=.49). CONCLUSIONS: This study has confirmed the comparable efficacy and tolerability in using TACE for the treatment of advanced HCC in young and elderly patient populations. © 2009 American Cancer Society. |
Persistent Identifier | http://hdl.handle.net/10722/87630 |
ISSN | 2023 Impact Factor: 6.1 2023 SCImago Journal Rankings: 2.887 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yau, T | en_HK |
dc.contributor.author | Yao, TJ | en_HK |
dc.contributor.author | Chan, P | en_HK |
dc.contributor.author | Epstein, RJ | en_HK |
dc.contributor.author | Ng, KK | en_HK |
dc.contributor.author | Chok, KSH | en_HK |
dc.contributor.author | Cheung, TT | en_HK |
dc.contributor.author | Fan, ST | en_HK |
dc.contributor.author | Poon, RTP | en_HK |
dc.date.accessioned | 2010-09-06T09:32:18Z | - |
dc.date.available | 2010-09-06T09:32:18Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Cancer, 2009, v. 115 n. 23, p. 5507-5515 | en_HK |
dc.identifier.issn | 0008-543X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/87630 | - |
dc.description.abstract | BACKGROUND: The authors evaluated and compared the treatment outcomes of transarterial chemoembolization (TACE) between young (≤70 years) and elderly (>70 years) patients at their institute over an 18-year period. METHODS: Advanced hepatocellular carcinoma (HCC) patients who received TACE at the authors' center were analyzed retrospectively. The demographic data, TACE-related morbidities, and survival outcome were compared between these 2 age groups. RESULTS: Between 1989 and 2006, 843 patients who were ≤70 years old and 197 patients who were >70 years old received TACE treatment for advanced HCC. There were significantly more comorbid illnesses associated with the elderly patients than the young patients (64 % vs 33%, P < .01). Moreover, elderly patients who received TACE treatment for HCC were at earlier stages of disease (P < .01). Both the overall median survival (14.0 months vs 8.1 months, P < .003) and disease-specific survival (15.2 months vs 8.7 months, P < .001) were significantly higher in elderly than young patients. The most commonly encountered TACE-related morbidity in both age groups was liver function derangement. Young patients had a significantly higher rate of developing liver derangement after TACE than elderly patients (21% vs 11%, P < .01). Conversely, the elderly patients had a significantly higher rate of developing peptic ulcer disease with TACE treatment than young patients (2.5% vs 0.5%, P=.01). Overall, there was no significant difference in TACE-related mortality between the young and elderly patients (3% vs 4%, P=.49). CONCLUSIONS: This study has confirmed the comparable efficacy and tolerability in using TACE for the treatment of advanced HCC in young and elderly patient populations. © 2009 American Cancer Society. | en_HK |
dc.language | eng | en_HK |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741 | en_HK |
dc.relation.ispartof | Cancer | en_HK |
dc.subject | Elderly | en_HK |
dc.subject | Hepatitis | en_HK |
dc.subject | Hepatocellular carcinoma | en_HK |
dc.subject | Transarterial chemoembolization | en_HK |
dc.subject.mesh | Carcinoma, Hepatocellular - mortality - therapy | - |
dc.subject.mesh | Chemoembolization, Therapeutic - adverse effects - mortality | - |
dc.subject.mesh | Infusions, Intra-Arterial | - |
dc.subject.mesh | Liver Neoplasms - mortality - therapy | - |
dc.subject.mesh | Survival Analysis | - |
dc.title | The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0008-543X&volume=115&issue=23&spage=5507&epage=5515&date=2009&atitle=The+outcomes+of+elderly+patients+with+hepatocellular+carcinoma+treated+with+transarterial+chemoembolization | en_HK |
dc.identifier.email | Yau, T: tyaucc@hku.hk | en_HK |
dc.identifier.email | Yao, TJ: tjyao@hkucc.hku.hk | en_HK |
dc.identifier.email | Epstein, RJ: repstein@hku.hk | en_HK |
dc.identifier.email | Fan, ST: stfan@hku.hk | en_HK |
dc.identifier.email | Poon, RTP: poontp@hku.hk | en_HK |
dc.identifier.authority | Yau, T=rp01466 | en_HK |
dc.identifier.authority | Yao, TJ=rp00284 | en_HK |
dc.identifier.authority | Epstein, RJ=rp00501 | en_HK |
dc.identifier.authority | Fan, ST=rp00355 | en_HK |
dc.identifier.authority | Poon, RTP=rp00446 | en_HK |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1002/cncr.24636 | en_HK |
dc.identifier.pmid | 19701904 | - |
dc.identifier.scopus | eid_2-s2.0-72249100065 | en_HK |
dc.identifier.hkuros | 168444 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-72249100065&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 115 | en_HK |
dc.identifier.issue | 23 | en_HK |
dc.identifier.spage | 5507 | en_HK |
dc.identifier.epage | 5515 | en_HK |
dc.identifier.isi | WOS:000271918600020 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Yau, T=23391533100 | en_HK |
dc.identifier.scopusauthorid | Yao, TJ=7401886444 | en_HK |
dc.identifier.scopusauthorid | Chan, P=7403497715 | en_HK |
dc.identifier.scopusauthorid | Epstein, RJ=34975074500 | en_HK |
dc.identifier.scopusauthorid | Ng, KK=35248894000 | en_HK |
dc.identifier.scopusauthorid | Chok, SH=6602753231 | en_HK |
dc.identifier.scopusauthorid | Cheung, TT=36847499900 | en_HK |
dc.identifier.scopusauthorid | Fan, ST=7402678224 | en_HK |
dc.identifier.scopusauthorid | Poon, RTP=7103097223 | en_HK |
dc.identifier.issnl | 0008-543X | - |